Keyphrases
Lenvatinib
48%
Hepatocellular Carcinoma
45%
Japan
45%
Crohn's Disease
41%
Unresectable Hepatocellular Carcinoma
41%
Ulcerative Colitis
41%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
40%
Confidence Interval
32%
Atezolizumab Plus Bevacizumab
29%
Adverse Events
27%
Inflammatory Bowel Disease
27%
Tumor
24%
Hepatocellular Carcinoma Patients
22%
Malignant Biliary Obstruction
21%
Overall Survival
21%
Endoscopic Papillary Large Balloon Dilatation (EPLBD)
21%
Endoscopic Ultrasound-guided
20%
Chemotherapy
19%
Liver
19%
Advanced Gastric Cancer
18%
Common Bile Duct Stones
18%
Endoscopic Sphincterotomy
17%
Hazard Ratio
17%
Multivariate Analysis
16%
Progression-free Survival
15%
Helicobacter Pylori (H. pylori)
15%
Advanced Hepatocellular Carcinoma
15%
Endoscopic Ultrasonography
15%
Pancreatitis
15%
Japanese Patients
15%
Recurrent Biliary Obstruction
15%
Odds Ratio
14%
Gastric Cancer
14%
Endoscopic Surgery
14%
Endoscopic Retrograde Cholangiopancreatography
13%
Endoscopic Ultrasound
13%
Gemcitabine
12%
Albumin-bilirubin Grade
12%
Sorafenib
12%
Stent
12%
Risk Factors
12%
Benign Biliary Stricture
12%
Pancreatic Cancer
11%
Bile Duct Stones
11%
Walled-off
11%
Prospective Randomized Trial
11%
Cisplatin
11%
Clinical Outcomes
11%
Multicenter Cohort Study
10%
Pathological Diagnosis
10%
Multicenter Retrospective Study
10%
Methylation Status
10%
Endoscopic Management
10%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
Radiofrequency Ablation
10%
Stricture
10%
Older Women
10%
Ultrasonographic Guidance
10%
Nonalcoholic Steatohepatitis
9%
Liver Disease
9%
Colonoscopy
9%
Biliary Stenting
9%
Gastric mucosa
9%
Phase II Study
9%
Older Men
9%
Predictive Factors
9%
Biopsy Specimen
9%
Randomized Controlled Trial
9%
Bevacizumab
9%
Prospective pilot Study
8%
Methylation
8%
Multicenter Randomized Controlled Trial
8%
Hepatic Function
8%
Endoscopic Diagnosis
8%
Adalimumab
8%
Double-balloon Enteroscopy
8%
Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD)
8%
EUS-guided
8%
Monoclonal Antibody
8%
Bleeding
8%
Prognostic Factors
8%
Small Intestine
8%
Stent Placement
8%
No Significant Difference
8%
Median Progression-free Survival
8%
Clinical Features
8%
Combination Therapy
8%
Acyclic Retinoid
8%
Pancreatic Cancer Cells
8%
Plastic Stent
8%
Meta-analysis
8%
Consecutive Patients
8%
Gastrointestinal Stromal Tumor
8%
DNA Methylation (DNAm)
8%
Helicobacter Pylori Infection
8%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
7%
Hepatitis B Virus
7%
Covered Self-expandable Metallic Stent
7%
Necrosis
7%
Guidewire
7%
Medicine and Dentistry
Hepatocellular Carcinoma
84%
Endoscopic Ultrasound
63%
Cholestasis
48%
Lenvatinib
43%
Neoplasm
39%
Adverse Event
38%
Endoscopic Ultrasound Guided Fine Needle Biopsy
37%
Balloon Dilatation
26%
Ulcerative Colitis
26%
Disease
25%
Diagnosis
24%
Overall Survival
24%
Bevacizumab
22%
Crohn's Disease
22%
Atezolizumab
21%
Biopsy Technique
21%
Abdominal Cancer
21%
Common Bile Duct Stone
21%
Stenting
19%
Endoscopic Retrograde Cholangiopancreatography
19%
Chemotherapy
19%
Patient with Ulcerative Colitis
18%
Pancreatitis
18%
Endoscopic Sphincterotomy
17%
Fine-Needle Aspiration
17%
Pancreas Cancer
16%
Randomized Controlled Trial
16%
Self-Expandable Metallic Stent
16%
Inflammatory Bowel Disease
15%
Patient with Crohn's Disease
15%
Progression Free Survival
15%
Biliary Tract Drainage
14%
Lymphocyte
14%
Hazard Ratio
14%
Pancreatic Duct
13%
Endoscopy
13%
Colonoscopy
13%
Radiofrequency Ablation
12%
Stricture
12%
Nonalcoholic Fatty Liver
12%
Bile Duct Stone
12%
Retrospective Study
12%
Multivariate Analysis
12%
Liver Function
11%
Computer Assisted Tomography
11%
Bleeding
11%
Malignant Neoplasm
11%
Recurrent Disease
11%
Cancer
11%
Odds Ratio
10%
Bilirubin
10%
Clinical Trial
10%
Necrosis
10%
Surgery
10%
Patient with Inflammatory Bowel Disease
9%
Stent Placement
9%
Cholangiocarcinoma
9%
Magnetic Resonance Imaging
9%
Ulcer
9%
Bile Duct
9%
Infection
8%
Liver Cirrhosis
8%
Capsule Endoscopy
8%
Cohort Analysis
8%
Cannulation
8%
Prospective Study
8%
Liver Disease
8%
Predictive Factor
8%
Sclerosing Cholangitis
8%
Neutrophil
7%
Prognostic Factor
7%
Immunoglobulin G4
7%
Stenosis
7%
Arm
7%
Diagnostic Accuracy
7%
Biliary Tract Endoscopy
7%
Helicobacter Pylori
7%
Clinical Feature
7%
Celiac Plexus Neurolysis
7%
Double-Balloon Enteroscopy
6%
Sorafenib
6%
Endoscopic Submucosal Dissection
6%
Chronic Pancreatitis
6%
Differential Diagnosis
6%
Extracorporeal Shock Wave Lithotripsy
6%
Placebo
6%
Hepatitis B Virus
6%
Quality of Life
6%
Lithotripsy
6%
Echography
6%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
6%
Liver Cancer
6%
Histology
6%
Ascites
6%
Diffuse Large B-Cell Lymphoma
6%
Retrospective Cohort Study
6%
Acute Pancreatitis
6%
Combination Therapy
6%
Meta-Analysis
5%
Cholangitis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Lenvatinib
46%
Bevacizumab
37%
Atezolizumab
36%
Overall Survival
35%
Adverse Event
32%
Abdominal Cancer
29%
Chemotherapy
27%
Crohn's Disease
26%
Ulcerative Colitis
25%
Progression Free Survival
24%
Disease
22%
Neoplasm
21%
Pancreas Cancer
18%
Combination Therapy
16%
Inflammatory Bowel Disease
16%
Remission
15%
Bilirubin
14%
Malignant Neoplasm
14%
Sorafenib
13%
Gemcitabine
12%
Retrospective Study
11%
Nonalcoholic Fatty Liver
11%
Helicobacter Pylori
10%
Cisplatin
10%
Diffuse Large B Cell Lymphoma
10%
Retinoid
10%
Clinical Trial
9%
Tumor Necrosis Factor
8%
Liver Disease
8%
Epidermal Growth Factor Receptor
8%
Monotherapy
8%
Biological Marker
8%
Liver Injury
8%
Placebo
7%
Liver Cancer
7%
Colon Carcinoma
7%
Adalimumab
7%
Injury
7%
Ulcer
6%
Normal Human
6%
Prospective Study
6%
Survival Rate
6%
Biliary Tract Cancer
6%
Rituximab
6%
Hepatitis B Virus
6%
Liver Cirrhosis
6%
Infection
6%
Pancreatitis
6%
Fluoropyrimidine
6%
Common Bile Duct Stone
5%
Liver Fibrosis
5%
Fluorouracil
5%
Ascites
5%
Recurrent Disease
5%
Mercaptopurine
5%
Infliximab
5%
Ramucirumab
5%
Fetoprotein
5%
Hepatitis C Virus
5%
Irinotecan
5%
Messenger RNA
5%
Doxorubicin
5%
Non-Steroidal Anti-Inflammatory Drug
5%
Gastric Mucosa
5%
Disease Activity
5%
Randomized Controlled Trial
5%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%